Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I-II neoadjuvant lapatinib + docetaxel after FEC in HER2-positive locally advanced or large operable breast cancer
2006-000864-94Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Sep 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lapatinib in breast cancer, sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Phase I maximum tolerated dose. Started Sep 2006; status: completed.
02
Drugs
lapatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2006-000864-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000864-94.